VEGFA and myocardial infarction: Recent reports also indicated that MSCs pre-treatment with angiotensin II enhances the outcome of MSC-based therapy for myocardial infarction (MI) in part via increasing the paracrine production of VEGF, and supporting gap junctions (GJs) [89].